Correction to “The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight”
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.